MDS Announces Resolution of Litigation Related to the Sale of MDS Analytical Technologies
January 25 2010 - 8:30AM
PR Newswire (US)
TORONTO, Jan. 25 /PRNewswire-FirstCall/ -- MDS Inc. (TSX: MDS;
NYSE: MDZ), a leading provider of products and services to the
global life sciences markets, today announced that PerkinElmer,
Inc. (NYSE:PKI) has, pursuant to a settlement agreement, agreed to
terminate its litigation against the Company, which was scheduled
to be heard in Commercial Court in Toronto today. MDS has a
joint-venture with PerkinElmer to develop, manufacture and sell
inductively coupled plasma mass spectrometers (ICP/MS). The sale of
MDS Analytical Technologies, which was announced on September 2,
2009, is expected to close before the end of the first calendar
quarter 2010, subject to receiving regulatory approvals and
satisfying closing conditions. About MDS MDS Inc. (TSX: MDS; NYSE:
MDZ) is a global life sciences company that provides market-leading
products and services that our customers need for the development
of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of innovative technologies for use in
medical imaging and radiotherapeutics, sterilization,
pharmaceutical contract research, and analytical instruments. MDS
has more than 3,500 highly skilled people in 13 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. Caution Concerning Forward-Looking Statements This
document contains forward-looking statements, including statements
with respect to the proposed sale of the MDS Analytical
Technologies business, and factors that may affect such proposed
sale. Some forward-looking statements may be identified by words
like "believes", "expects", "anticipates", "plans", "intends",
"indicates" or similar expressions. The statements are not a
guarantee that the proposed sale will be completed nor a guarantee
of future performance, and are inherently subject to risks and
uncertainties, including, but not limited to the risks and other
factors set forth in reports and other documents filed by MDS with
Canadian and U.S. securities regulatory authorities from time to
time, including MDS's quarterly and annual MD&A, Annual
Information Form, and Annual Report on Form 40-F for the fiscal
year ended October 31, 2008, filed with the U.S. Securities &
Exchange Commission and the Management Information Circular (dated
September 17, 2009). DATASOURCE: MDS Inc. CONTACT: MEDIA: Janet Ko,
(905) 267-4226, ; INVESTORS: Catherine Love, (905) 267-4230,
Copyright